Pharmaceuticals
Novo Nordisk cuts some U.S. supply of Wegovy being overweight drug as demand soars
Danish pharmaceutical company Novo Nordisk said Thursday it was slicing the source of starter doses of its weight problems drug Wegovy in the U.S. as it struggles to preserve up with surging demand from customers. Main Economic Officer Karsten Munk Knudsen told CNBC that halving the provide of Wegovy starter doses was supposed to make certain present patients could […]
Read More
FDA approves GSK’s RSV vaccine for older adults, world’s first shot against virus
A GSK lab in London. Oli Scarff | Getty Images The Food and Drug Administration on Wednesday approved an RSV vaccine produced by GlaxoSmithKline for use on adults ages 60 and older. The approval, the first ever globally by a regulatory body for an RSV vaccine, is a decisive victory for GSK in a race […]
Read More
J&J’s consumer health business Kenvue is going public this week. Here’s what to know
Johnson & Johnson products on a shelf in a store in New York. Lucas Jackson | Reuters Johnson & Johnson‘s consumer health business, Kenvue, is expected to go public this week in the largest U.S. IPO in more than a year. That business is chock full of household names familiar to investors and the larger […]
Read More
Pfizer earnings and revenue top expectations despite Covid vaccine sales decline
Pharmaceutical Pfizer Inc. said that an oral drug for treating COVID-19 could be available by end of 2021. Soumyabrata Roy | NurPhoto | Getty Images Pfizer on Tuesday reported first-quarter revenue and adjusted earnings that topped Wall Street’s expectations, despite a decline in sales driven by the lower demand for the company’s Covid vaccine. Pfizer’s […]
Read More
Being overweight drug marketplace could be really worth $200 billion in the decade, states Barclays, as sector valuations grow
The burgeoning pounds-decline drug market, which is whetting investors’ appetites with its pledge of combatting worldwide being overweight rates, could be value as a great deal as $200 billion inside of the following decade, in accordance to Barclays lender. Dubbing being overweight “the story of this ten years,” Barclays’ head of European pharmaceuticals fairness investigation […]
Read More
Merck revenue falls after dramatic drop in sales of Covid antiviral treatment
Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on October 4, 2021. NurPhoto | NurPhoto | Getty Images Merck on Thursday reported first-quarter revenue that fell 9% from the same period a year ago largely due to a steep drop in sales […]
Read More
The EU outlined its program to equalize drug obtain and lessen costs. Pharma companies are not happy
A molecular biologist examines wastewater samples for pathogens in the basic safety laboratory at the Max Delbrück Heart for Molecular Medicine in Mitte. Photo Alliance | Image Alliance | Getty Illustrations or photos The European Union on Wednesday introduced its prolonged-awaited overhaul of present pharmaceutical laws, reflecting the bloc’s most significant shake-up of rules governing […]
Read More
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen isn’t worried about competing with Eli Lilly as they both attempt to bring an Alzheimer’s drug to the market, Biogen’s CEO said Tuesday. “I think it will be good if there are […]
Read More
FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration on Tuesday granted accelerated approval for Biogen‘s drug tofersen, which treats a rare and aggressive form of the disease known as ALS. Accelerated approval is an FDA designation […]
Read More
Johnson & Johnson consumer health unit valued at $40 billion ahead of IPO, report says
Johnson & Johnson logo SOPA Images | LightRocket | Getty Images Johnson & Johnson‘s consumer health business is valued at $40 billion ahead of its initial public offering later this year, according to a report by The Wall Street Journal. The soon-to-be spinoff Kenvue aims to raise $3.5 billion or more in the offering, people […]
Read More